Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics, Inc.

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Dianthus Therapeutics, with a price target of $122.00. According to...

Wedbush Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alphatec Holdings (ATEC), Tyra Bioscience (TYRA) and...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNTH	$108.92	-0.91%	570.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNTH	$108.92	-0.9%	570.47K
3
4
5
6

DNTH

DNTH

Get Dianthus Therapeutics, Inc. Data in Excel

Get Dianthus Therapeutics, Inc. Data in Excel